Ezekowitz Alan 4

What Happened Alan Ezekowitz, a director of Fulcrum Therapeutics (FULC), was granted a derivative award covering 32,000 shares on June 30, 2026. The reported grant shows an acquisition price of $0.00 (no cash paid at grant); the entry is coded as an award/grant (A) rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-30; Form 4 filed 2026-07-02 (filed within the standard two-business-day window).
• Award: 32,000-share option/derivative; reported price $0.00 at grant.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The option vests in full on the first anniversary of the grant or, if earlier, immediately prior to the first annual meeting of stockholders after the grant, subject to continued service.
• Transaction type code: A (award/grant); this is a grant of rights (not an exercise or sale).

Context This is a standard equity compensation grant to a board member and does not represent an immediate market purchase or sale. Because the award vests in the future, it only becomes the director’s economic interest if and when vesting conditions are met (and any subsequent exercises or sales would be reported separately).